Landmark filing for Kyowa Kirin's first antibody
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has made the first regulatory filing worldwide for its lead biologic, the novel anti-CCR4 antibody KW-0761, for the treatment of adult T-cell leukaemia/lymphoma (ATL).